This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Cardiolite
- Generic Name
- Tetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate
Commonly known or available as Cardio-spect - DrugBank Accession Number
- DB14106
- Background
Tetrakis (2-methoxyisobutylisocyanide) copper (I) tetrafluoroborate is a component of Cardiolite, a technetium Tc99m-based imaging agent used for assessing myocardial perfusion.1
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Tetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate (DB14106)
- Weight
- Average: 602.99
Monoisotopic: 602.268772 - Chemical Formula
- C24H44BCuF4N4O4
- Synonyms
- Cardio-spect
- Tetrakis (2-methoxyisobutyl isonitrile) copper (I) tetrafluoroborate
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Cardiolite Injection, powder, lyophilized, for solution 1 mg/1mL Intravenous Lantheus Medical Imaging, Inc. 1990-12-20 Not applicable US 
Kit for the Preparation of Technetium Tc99m Sestamibi Injection, powder, lyophilized, for solution 1 mg/1mL Intravenous Lantheus Medical Imaging, Inc. 1990-12-20 Not applicable US Sestamibi Injection, powder, lyophilized, for solution 1.5 mg/1 Intravenous Anazao Health Corporation 2012-05-23 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Technetium Tc 99m Sestamibi Injection 1 mg/1mL Intravenous Curium US LLC 2011-10-31 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Sestamibi Tetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate (1.5 mg/1) Injection, powder, lyophilized, for solution Intravenous Anazao Health Corporation 2012-05-23 Not applicable US
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- N6OU7HJ70P
- CAS number
- 103694-84-4
- InChI Key
- WJRFSUVOHUMYAO-UHFFFAOYSA-N
- InChI
- InChI=1S/4C6H11NO.BF4.Cu/c4*1-6(2,8-4)5-7-3;2-1(3,4)5;/h4*5H2,1-2,4H3;;/q;;;;-1;+1
- IUPAC Name
- lambda1-copper(1+) tetrakis(1-isocyano-2-methoxy-2-methylpropane) tetrafluoroboranuide
- SMILES
- [Cu+].F[B-](F)(F)F.COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-].COC(C)(C)C[N+]#[C-]
References
- General References
- FDA Approved Drug Products: Cardiolite (Kit for the Preparation of Technetium Tc99m Sestamibi) for injection [Link]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Diagnostic Coronary Artery Disease (CAD) / Type 1 Diabetes Mellitus 1 3 Completed Diagnostic Mucocutaneous Lymph Node Syndrome 1 0 Active Not Recruiting Diagnostic Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Triple Negative Breast Carcinoma 1 Not Available Completed Diagnostic Breast Cancer 2 Not Available Terminated Diagnostic Ischemic Heart Disease / Myocardial Infarction 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution; kit Intravenous 1 MG Injection, powder, lyophilized, for solution Intravenous Kit Injection, powder, lyophilized, for solution Intravenous 1 mg/vial Injection, powder, lyophilized, for solution Intravenous 1 mg/1mL Injection, powder, lyophilized, for solution Intravenous 1 mg Injection, powder, lyophilized, for solution Intravenous 1.5 mg/1 Kit 1 mg Injection, powder, for solution Intravenous 1.0 mg Injection, powder, for solution Intravenous 1 MG/vial Injection, powder, for solution Intravenous bolus 1 mg Injection Intravenous 1 mg/1mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0366 mg/mL ALOGPS logP 2.94 ALOGPS logP -1.3 Chemaxon logS -3.8 ALOGPS pKa (Strongest Acidic) 16.14 Chemaxon pKa (Strongest Basic) -4.2 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 13.59 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 41.61 m3·mol-1 Chemaxon Polarizability 12.7 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at June 21, 2018 16:28 / Updated at February 13, 2021 10:53